PortalPublikationenL1 is a potential marker for poorly-differentiated pancreati...

L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.

Standard

L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. / Kaifi, Jussuf; Zinnkann, Ulrich; Yekebas, Emre F; Schurr, Paulus; Reichelt, Uta; Wachowiak, Robin; Fiegel, Henning C; Petri, Susann; Schachner, Melitta; Izbicki, Jakob R.

in: WORLD J GASTROENTERO, Jahrgang 12, Nr. 1, 1, 2006, S. 94-98.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kaifi, J, Zinnkann, U, Yekebas, EF, Schurr, P, Reichelt, U, Wachowiak, R, Fiegel, HC, Petri, S, Schachner, M & Izbicki, JR 2006, 'L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.', WORLD J GASTROENTERO, Jg. 12, Nr. 1, 1, S. 94-98. <http://www.ncbi.nlm.nih.gov/pubmed/16440424?dopt=Citation>

APA

Kaifi, J., Zinnkann, U., Yekebas, E. F., Schurr, P., Reichelt, U., Wachowiak, R., Fiegel, H. C., Petri, S., Schachner, M., & Izbicki, J. R. (2006). L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. WORLD J GASTROENTERO, 12(1), 94-98. [1]. http://www.ncbi.nlm.nih.gov/pubmed/16440424?dopt=Citation

Vancouver

Kaifi J, Zinnkann U, Yekebas EF, Schurr P, Reichelt U, Wachowiak R et al. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. WORLD J GASTROENTERO. 2006;12(1):94-98. 1.

Bibtex

@article{61f204e5315243fb892d7251b4d6cd70,
title = "L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.",
abstract = "AIM: To determine the expression of L1 in pancreatic neuroendocrine tumor and to correlate it with WHO classification of this tumor. METHODS: We retrospectively analyzed L1 expression in 63 cases of pancreatic neuroendocrine tumor by immunohistochemistry on paraffin sections of primary tumors or metastases. Staining was performed by peroxidase technique with monoclonal antibody UJ127.11 against human L1. All tumors were classified according to WHO classification as well-differentiated neuroendocrine tumors and carcinomas or poorly-differentiated neuroendocrine carcinomas. RESULTS: L1 was detected in 5 (7.9%) of 63 pancreatic neuroendocrine tumors. Four (44.4%) of 9 poorly-differentiated carcinomas expressed L1. In contrast, only 1 (1.9%) of 54 well-differentiated tumors or carcinomas was positive for L1. No expression was found in Langerhans islet cells of normal pancreatic tissue. Cross table analysis showed a significant association between L1 expression and classification of neuroendocrine tumors of the pancreas (P",
author = "Jussuf Kaifi and Ulrich Zinnkann and Yekebas, {Emre F} and Paulus Schurr and Uta Reichelt and Robin Wachowiak and Fiegel, {Henning C} and Susann Petri and Melitta Schachner and Izbicki, {Jakob R}",
year = "2006",
language = "Deutsch",
volume = "12",
pages = "94--98",
journal = "WORLD J GASTROENTERO",
issn = "1007-9327",
publisher = "WJG Press",
number = "1",

}

RIS

TY - JOUR

T1 - L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.

AU - Kaifi, Jussuf

AU - Zinnkann, Ulrich

AU - Yekebas, Emre F

AU - Schurr, Paulus

AU - Reichelt, Uta

AU - Wachowiak, Robin

AU - Fiegel, Henning C

AU - Petri, Susann

AU - Schachner, Melitta

AU - Izbicki, Jakob R

PY - 2006

Y1 - 2006

N2 - AIM: To determine the expression of L1 in pancreatic neuroendocrine tumor and to correlate it with WHO classification of this tumor. METHODS: We retrospectively analyzed L1 expression in 63 cases of pancreatic neuroendocrine tumor by immunohistochemistry on paraffin sections of primary tumors or metastases. Staining was performed by peroxidase technique with monoclonal antibody UJ127.11 against human L1. All tumors were classified according to WHO classification as well-differentiated neuroendocrine tumors and carcinomas or poorly-differentiated neuroendocrine carcinomas. RESULTS: L1 was detected in 5 (7.9%) of 63 pancreatic neuroendocrine tumors. Four (44.4%) of 9 poorly-differentiated carcinomas expressed L1. In contrast, only 1 (1.9%) of 54 well-differentiated tumors or carcinomas was positive for L1. No expression was found in Langerhans islet cells of normal pancreatic tissue. Cross table analysis showed a significant association between L1 expression and classification of neuroendocrine tumors of the pancreas (P

AB - AIM: To determine the expression of L1 in pancreatic neuroendocrine tumor and to correlate it with WHO classification of this tumor. METHODS: We retrospectively analyzed L1 expression in 63 cases of pancreatic neuroendocrine tumor by immunohistochemistry on paraffin sections of primary tumors or metastases. Staining was performed by peroxidase technique with monoclonal antibody UJ127.11 against human L1. All tumors were classified according to WHO classification as well-differentiated neuroendocrine tumors and carcinomas or poorly-differentiated neuroendocrine carcinomas. RESULTS: L1 was detected in 5 (7.9%) of 63 pancreatic neuroendocrine tumors. Four (44.4%) of 9 poorly-differentiated carcinomas expressed L1. In contrast, only 1 (1.9%) of 54 well-differentiated tumors or carcinomas was positive for L1. No expression was found in Langerhans islet cells of normal pancreatic tissue. Cross table analysis showed a significant association between L1 expression and classification of neuroendocrine tumors of the pancreas (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 12

SP - 94

EP - 98

JO - WORLD J GASTROENTERO

JF - WORLD J GASTROENTERO

SN - 1007-9327

IS - 1

M1 - 1

ER -